Abstract
Background Combined intracoronary and intramyocardial administration might improve outcomes for bone-marrow-derived stem cell therapy for acute myocardial infarction (AMI). We compared the safety and feasibility of early and late delivery of stem cells with combined therapy approaches.
Methods Patients with left ventricular ejection fraction less than 45% after AMI were randomly assigned stem cell delivery via intramyocardial injection and intracoronary infusion 3–6 weeks or 3–4 months after AMI. Primary end points were changes in infarct size and left ventricular ejection fraction 3 months after therapy.
Results A total of 60 patients were treated. The mean changes in infarct size at 3 months were −3.5 ± 5.1% (95% CI −5.5% to −1.5%, P = 0.001) in the early group and −3.9 ± 5.6% (95% CI −6.1% to −1.6%, P = 0.002) in the late group, and changes in ejection fraction were 3.5 ± 5.6% (95% CI 1.3–5.6%, P = 0.003) and 3.4 ± 7.0% (95% CI 0.7–6.1%, P = 0.017), respectively. At 9–12 months after AMI, ejection fraction remained significantly higher than at baseline in both groups. In the early and late groups, a mean of 200.3 ± 68.7 × 106 and 194.8 ± 60.4 × 106 stem cells, respectively, were delivered to the myocardium, and 1.30 ± 0.68 × 109 and 1.29 ± 0.41 × 109 cells, respectively, were delivered into the artery. A high number of cells was required for significant improvements in the primary end points.
Conclusions Combined cardiac stem cell delivery induces a moderate but significant improvement in myocardial infarct size and left ventricular function.
Key Points
-
The combined (intramyocardial followed by intracoronary) application of cardiac BM-MNC therapy is safe and feasible in patients with recent AMI and severely depressed left ventricular function
-
Both early (mean 32 days post-AMI) and late (mean 93 days post-AMI) treatment resulted in an improvement in infarct size and global ejection fraction, with temporary significant benefit of the early therapy
-
The 9–12 months control revealed a sustained beneficial effect of the combined delivery of the BM-MNC on left ventricular function
-
A reduction of infarct size was achieved in 76.6% and 70% of patients in Early and Late groups respectively, with 66.7% of patients in both groups showing improvement in global ejection fraction 3 months after cardiac delivery of BM-MNC
-
The total number of intramyocardially injected BM-MNC proved to be a statistically significant predictor of the reduction of infarct size
-
For a 5% decrease in infarct size, at least 219 × 106 intramyocardially injected BM-MNC and 4.29 × 106 CD34+ cells are required
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Orlic D et al. (2001) Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci USA 98: 10344–10349
Asahara T et al. (1999) Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 85: 221–228
Fernandez-Aviles F et al. (2004) Experimental and clinical regenerative capability of human bone marrow cells after myocardial infarction. Circ Res 95: 742–748
Strauer B et al. (2002) Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 106: 1913–1918
Assmus B et al. (2002) Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation 106: 3009–3017
Wollert KC et al. (2004) Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 364: 141–148
Chen SL et al. (2004) Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol 94: 92–95
Bartunek J et al. (2007) Pretreatment of adult bone marrow mesenchymal stem cells with cardiomyogenic growth factors and repair of the chronically infarcted myocardium. Am J Physiol Heart Circ Physiol 292: H1095–H1104
Schächinger V et al. (2006) Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 355: 1210–1221
Janssens S et al. (2006) Bone marrow cell transfer in acute myocardial infarction. Nat Clin Pract Cardiovasc Med 3: S69–S72
Lunde K et al. (2006) Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med 355: 1199–1209
Ripa RS et al. (2006) Stem cell mobilization induced by subcutaneous granulocyte-colony stimulating factor to improve cardiac regeneration after acute ST-elevation myocardial infarction: result of the double-blind, randomized, placebo-controlled Stem Cells In Myocardial Infarction (STEMMI) trial. Circulation 113: 1983–1992
Dimmeler J et al. (2005) Unchain my heart: the scientific foundations of cardiac repair J Clin Invest 115: 572–583
Abdel-Latif A et al. (2007) Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch Intern Med 167: 989–997
Hou D et al. (2005) Radiolabeled cell distribution after intramyocardial, intracoronary, and interstitial retrograde coronary venous delivery: implications for current clinical trials. Circulation 112 (Suppl I): 1150–1156
Perin EC et al. (2003) Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation 107: 2294–2302
Tse HF et al. Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation. Lancet 361: 47–49
Fuchs S et al. (2003) Catheter-based autologous bone marrow myocardial injection in no-option patients with advanced coronary artery disease: a feasibility study. J Am Coll Cardiol 41: 1721–1724
Beeres SL et al. (2006) Usefulness of intramyocardial injection of autologous bone marrow-derived mononuclear cells in patients with severe angina pectoris and stress-induced myocardial ischemia. Am J Cardiol 97: 1326–1331
Silva GV et al. (2004) Catheter-based transendocardial delivery of autologous bone-marrow-derived mononuclear cells in patients listed for heart transplantation. Tex Heart Inst J 31: 214–219
Charwat S et al. (2008) Role of adult bone marrow stem cells in the repair of ischemic myocardium: current state of the art. Exp Haematol 36: 672–680
Nyolczas N et al. (2007) Design and rationale for the Myocardial Stem Cell Administration After Acute Myocardial Infarction (MYSTAR) Study: a multicenter, prospective, randomized, single-blind trial comparing early and late intracoronary or combined (percutaneous intramyocardial and intracoronary) administration of nonselected autologous bone marrow cells to patients after acute myocardial infarction. Am Heart J 153: 212.e1–e7
Baxter GF (2002) The neutrophil as a mediator of myocardial ischemia-reperfusion injury: time to move on. Basic Res Cardiol 97: 268–275
Frangogiannis NG et al. (2002) The inflammatory response in myocardial infarction. Cardiovasc Res 53: 31–47
Boden WE et al. (1995) Incomplete, delayed functional recovery late after reperfusion following acute myocardial infarction: “maimed myocardium”. Am Heart J 130: 922–932
Schulz R et al. (2001) Balance and imbalance of regional myocardial contractile function and blood flow. Z Kardiol 90: 964–969
Bax JJ et al. (2001) Time course of functional recovery of stunned and hibernating segments after surgical revascularization. Circulation 104 (Suppl I): I314–1318
Gyöngyösi M et al. (2005) Characterization of hibernating myocardium with NOGA electroanatomic endocardial mapping. Am J Cardiol 95: 722–728
Armstrong WF et al. (1998) Stress echocardiography: recommendations for performance and interpretation of stress echocardiography. J Am Soc Echocardiogr 11: 97–104
Ben Haim SA et al. (1996) Nonfluoroscopic, in vivo navigation and mapping technology. Nat Med 2: 1393–1395
Gepstein L et al. (1997) A novel method for nonfluoroscopic catheter-based electroanatomical mapping of the heart: in vitro and in vivo accuracy results. Circulation 95: 1611–1622
Gyöngyösi M et al. (2001) Online myocardial viability assessment in the catheterization laboratory via NOGA electroanatomic mapping: quantitative comparison with thallium-201 uptake. Circulation 104: 1005–1011
Gyöngyösi M et al. (2005) NOGA-guided analysis of regional myocardial perfusion abnormalities treated with intramyocardial injections of plasmid encoding vascular endothelial growth factor A-165 in patients with chronic myocardial ischemia: subanalysis of the EUROINJECT-ONE multicenter double-blind randomized study. Circulation 112 (Suppl I): I157–I65
SPSS® version 11.0 (Nie NH and Hadlai HC, Chicago, IL)
Aicher A et al. (2003) Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med 9: 1370–1376
Hill JM et al. (2003) Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 348: 593–600
Losordo DW et al. (2007) Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial. Circulation 115: 3165–3172
Gibbons RJ et al. (2000) Infarct size measured by single photon emission computed tomographic imaging with 99Tc-sestamibi: a measure of the efficacy of therapy in acute myocardial infarction. Circulation 101: 101–108
Solomon SD et al. (2001) Recovery of ventricular function after myocardial infarction in the reperfusion era: the Healing and Early Afterload Reducing Therapy Study. Ann Intern Med 134: 451–458
Kalla K et al. (2006) Vienna STEMI Registry Group. Implementation of guidelines improves the standard of care: the Viennese Registry on Reperfusion Strategies in ST-Elevation Myocardial Infarction (Vienna STEMI registry). Circulation 113: 2398–2405
Acknowledgements
This study was supported by the Österreichischer Herzfond (project number 05/059), an educational grant from the OMAA (Austrian-Hungarian Action Foundation, project number 60öu7), and the Austrian Society of Cardiology.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Gyöngyösi, M., Lang, I., Dettke, M. et al. Combined delivery approach of bone marrow mononuclear stem cells early and late after myocardial infarction: the MYSTAR prospective, randomized study. Nat Rev Cardiol 6, 70–81 (2009). https://doi.org/10.1038/ncpcardio1388
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncpcardio1388
This article is cited by
-
Stem cells therapy in acute myocardial infarction: a new era?
Clinical and Experimental Medicine (2021)
-
The role of stem cells in treating coronary artery disease in 2018
Indian Journal of Thoracic and Cardiovascular Surgery (2018)
-
Three dimensional fusion of electromechanical mapping and magnetic resonance imaging for real-time navigation of intramyocardial cell injections in a porcine model of chronic myocardial infarction
The International Journal of Cardiovascular Imaging (2016)
-
Timing for intracoronary administration of bone marrow mononuclear cells after acute ST-elevation myocardial infarction: a pilot study
Stem Cell Research & Therapy (2015)
-
An Update on Stem Cell Therapies for Acute Coronary Syndrome
Current Cardiology Reports (2014)